Filgrastim: Nursing Drug Guide, Splenic Rupture & NCLEX Review
Filgrastim stimulates neutrophil recovery after myelosuppressive chemotherapy—but splenic rupture can be fatal, and giving it within 24 hours before or after cytotoxic chemotherapy is unsafe. Nurses must confirm chemotherapy timing, trend the absolute neutrophil count (ANC), and stop therapy when ANC exceeds 10,000/mm³ after the nadir per Neupogen labeling.
Neupogen (filgrastim) labeling reports splenic rupture, including fatal cases, after filgrastim products. Evaluate immediately when a patient reports left upper abdominal or shoulder pain. Do not administer filgrastim in the 24-hour period before or after cytotoxic chemotherapy. Discontinue when ANC increases beyond 10,000/mm³ after the chemotherapy-induced nadir to avoid excessive leukocytosis.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every filgrastim dose, confirm chemotherapy ended >24 hours ago, review the latest CBC/ANC trend, and assess for left upper quadrant or shoulder pain. Hold and clarify when ANC is already >10,000/mm³, the patient has signs of splenic rupture or ARDS, or a serious allergic reaction occurred. Bone pain is common—splenic and pulmonary emergencies are not.
Most common brand names
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF). Brand and biosimilar names vary by region and formulary—verify the vial or prefilled syringe label against the MAR every time.
Common products include Neupogen (filgrastim), biosimilars such as Zarxio, Nivestym, and Releuko, and Granix (tbo-filgrastim). Pegfilgrastim (long-acting G-CSF) is a different product with different scheduling—do not substitute without prescriber and pharmacy approval.
Why we give it — Indications
Neupogen (filgrastim) is indicated to reduce neutropenia-related complications in selected oncology, transplant, mobilization, severe chronic neutropenia, and radiation-exposure settings. Oncology inpatient nurses most often see it after myelosuppressive chemotherapy and during bone marrow transplant recovery pathways.
| Use | Detail |
|---|---|
| Chemotherapy-induced neutropenia | Decrease incidence of infection manifested by febrile neutropenia in nonmyeloid malignancies (including breast cancer and lung cancer regimens) receiving myelosuppressive anticancer drugs associated with significant severe neutropenia with fever per Neupogen labeling. |
| Bone marrow transplantation & other labeled uses | Reduce duration of neutropenia after myeloablative chemotherapy and BMT (10 mcg/kg/day IV); also labeled for acute myelogenous leukemia (AML) induction/consolidation support, peripheral blood progenitor cell mobilization, severe chronic neutropenia, and myelosuppressive radiation exposure per full prescribing information. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Filgrastim binds G-CSF receptors on hematopoietic cells, stimulating proliferation and differentiation of neutrophil progenitors and enhancing selected neutrophil functions. A transient neutrophil rise often appears 1–2 days after starting therapy; sustained benefit requires daily dosing through the expected chemotherapy nadir per Neupogen labeling.
Dosing overview
Dosing is weight-based (mcg/kg) and indication-specific. Always confirm the patient’s current weight, last chemotherapy date/time, and latest CBC before preparing the dose.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber/pharmacy and follow institutional oncology protocol.
Before you give it — Safety check
Pretreatment checks
- Confirm cytotoxic chemotherapy was completed >24 hours ago and next cycle is not due within 24 hours—review MAR and infusion records
- Review latest complete blood count (CBC) / ANC trend; hold if ANC already >10,000/mm³ after nadir per labeling
- Allergy history to filgrastim, pegfilgrastim, or E. coli–derived proteins; abdominal/spleen exam baseline; perform medication reconciliation to prevent duplicate G-CSF products
Contraindications
- History of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim
- Scheduled cytotoxic chemotherapy within the 24-hour window before or after the planned filgrastim dose (do not administer)
- Not specified in the reviewed prescribing information for other absolute contraindications—use caution and prescriber guidance in sickle cell disorders, MDS/AML risk settings, and cutaneous vasculitis per warnings
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Cytotoxic chemotherapy (timing) | Safety and efficacy not established when given simultaneously; rapidly dividing myeloid cells are chemo-sensitive | Never give within 24 hours before through 24 hours after chemotherapy; clarify MAR timing with pharmacy |
| Pegfilgrastim / duplicate G-CSF therapy | Long-acting pegfilgrastim uses a different schedule; overlapping or substituted G-CSF products increase leukocytosis risk without coordinated orders | Reconcile MAR with pharmacy; verify only one G-CSF product per cycle unless prescriber documents dual therapy |
| PBPC mobilization with chemotherapy | Leukocyte counts may exceed 100,000/mm³ during mobilization per labeling | Monitor CBC during mobilization; discontinue filgrastim if WBC rises to >100,000/mm³ per Neupogen labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Subcutaneous injection or intravenous infusion per Neupogen labeling (single-dose vials and prefilled syringes for SC; vials may be diluted for IV)
- Remove from refrigerator; allow to reach room temperature 30 minutes up to 24 hours; discard if at room temperature >24 hours
- Inspect solution—clear and colorless; do not use if particulates or discoloration present; do not shake
- Document exact mcg administered, weight used for calculation, route, SC site or IV rate, and chemotherapy timing verification
Neupogen labeling directs administration at least 24 hours after cytotoxic chemotherapy and prohibits dosing in the 24-hour period before chemotherapy. If timing is unclear, hold and clarify with oncology pharmacy before injection.
Expected therapeutic response
- Rise in ANC after chemotherapy-induced nadir—often visible within 1–2 days of starting filgrastim
- Reduced duration/severity of severe neutropenia and febrile neutropenia when used with appropriate myelosuppressive regimens per trials
- Common bone or musculoskeletal pain may appear—distinguish from splenic rupture (left upper quadrant/shoulder pain) and respiratory emergencies
Red flags — Stop and act
Splenic rupture, ARDS, and hypersensitivity can escalate quickly. Hold filgrastim and activate emergency pathways when these cues appear.
- Left upper abdominal pain or left shoulder pain—possible splenomegaly or splenic rupture (may be fatal)
- Fever with new pulmonary infiltrates, hypoxia, or difficulty breathing—evaluate for ARDS; discontinue filgrastim
- Anaphylaxis, angioedema, bronchospasm, or widespread allergic rash—stop permanently per contraindication pattern
- Sickle cell crisis symptoms in patients with sickle cell disorders—discontinue filgrastim per labeling
- ANC >10,000/mm³ after chemotherapy nadir or WBC >100,000/mm³—excessive leukocytosis; discontinue per labeling and notify prescriber
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Bone / musculoskeletal pain | Most common in chemotherapy trials (e.g., arthralgia, back pain, bone pain, muscle spasms) | Assess with pain assessment; treat per prescriber; differentiate from splenic or pulmonary emergencies |
| Splenomegaly / splenic rupture | Rare but can be fatal; reported in adults and children | Evaluate left upper abdominal or shoulder pain; discontinue if rupture suspected; urgent imaging/surgical pathway per protocol |
| Acute respiratory distress syndrome (ARDS) | Reported with filgrastim products | Hold drug; evaluate fever, infiltrates, or respiratory distress; escalate per respiratory emergency protocol |
| Serious allergic reactions | Anaphylaxis, rash, urticaria reported | Stop permanently if serious reaction; treat per emergency protocol |
| Leukocytosis (WBC >100,000/mm³) | <5% of patients at doses above 5 mcg/kg/day in trials; usually without clinical sequelae | Monitor CBC; discontinue when ANC >10,000/mm³ after nadir per labeling |
| Cutaneous vasculitis | Reported, often with long-term SCN therapy | Hold filgrastim; resume at reduced dose only when symptoms resolve and ANC decreases per prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Neupogen labeling states the maximum tolerated dose has not been determined. WBC counts >100,000/mm³ were reported in <5% of chemotherapy patients but were not associated with adverse clinical effects in those reports. BMT patients received up to 138 mcg/kg/day without toxic effects, although dose response flattened above 10 mcg/kg/day.
Management
- No specific antidote is listed in the reviewed prescribing information
- Discontinue or reduce filgrastim; monitor CBC until counts normalize per prescriber
- Evaluate for leukocytosis-related complications and splenic enlargement if symptomatic
- Contact local poison control or medical toxicology services for additional guidance per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Filgrastim vs pegfilgrastim (Neulasta)—daily short-acting vs pegylated once-per-cycle; verify MAR product and schedule independently
- Filgrastim vs sargramostim (GM-CSF)—different colony-stimulating factor; independent double-check before refrigerator pick
- Filgrastim vs erythropoietin—both stored in oncology refrigerators; confirm patient name, drug name, and mcg/kg dose
- Biosimilars (Zarxio, Nivestym, Releuko) vs Neupogen—interchange only per pharmacy and prescriber policy; document exact product administered
- mcg/kg calculation errors—weight-based dosing from prefilled syringes (300 mcg or 480 mcg); pharmacy should verify when possible
- 24-hour chemotherapy window—scheduling filgrastim within 24 hours before or after cytotoxic chemotherapy is a high-risk timing error
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Storage | Refrigerate; allow 30 minutes to 24 hours at room temperature before use; discard if left at room temperature >24 hours per Neupogen labeling |
| SC technique | Rotate sites; do not shake; inspect for particulates—clear, colorless solution only |
| IV infusion | Short IV infusion 15–30 minutes or continuous infusion per order; diluted solution stable 24 hours at room temperature including infusion time |
| Chemo timing | Confirm last chemotherapy ended >24 hours ago and next cycle is not due within 24 hours before administering |
| Commonly missed | Giving within the 24-hour chemo blackout; continuing when ANC >10,000/mm³; dismissing left shoulder pain as musculoskeletal only |
| Ask pharmacy when | Biosimilar substitution, unclear mcg/kg dose from prefilled syringe, or hold/resume after splenic symptoms or leukocytosis |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pediatric oncology patients | Splenomegaly and hepatosplenomegaly reported in pediatric chemotherapy studies; monitor abdominal exam and pain complaints |
| Sickle cell disease / trait | Severe and sometimes fatal sickle cell crises reported—discontinue if crisis occurs |
| Breast / lung cancer with chemo-radiation | Monitor for MDS/AML signs per labeling when filgrastim used with chemotherapy and/or radiotherapy; also applies to congenital neutropenia subsets |
| Pregnancy | Available human data have not established an association with major birth defects or miscarriage; transplacental passage reported when given ≤30 hours before preterm delivery. Animal data show adverse rabbit fetal effects at 2–10× human doses. Use only if potential benefit justifies fetal risk. |
| Lactation | Filgrastim transfers into human milk in published reports; limited case reports note no infant adverse effects. Consider breastfeeding benefits, maternal clinical need, and potential infant exposure—consult prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- CBC with differential and platelets before starting and at least twice weekly during therapy per chemotherapy labeling
- ANC trend relative to 10,000/mm³ discontinuation threshold after nadir; WBC >100,000/mm³ on mobilization protocols
- Abdominal exam, spleen size symptoms, respiratory status, and pain scores (bone pain vs splenic pain pattern)
Document
- Weight, calculated mcg/kg dose, product name (including biosimilar), route, site, and time relative to last chemotherapy
- Pre-dose ANC/WBC and prescriber hold parameters; reason if dose held or discontinued
- Patient teaching on splenic pain, fever/infection reporting, and when to call before next injection
Patient teaching
- Report left upper stomach or left shoulder pain immediately—could signal spleen problems including rupture
- Bone or muscle aching is common; ask how to manage pain per prescriber and when pain pattern changes
- Seek urgent care for breathing problems, facial swelling, or severe rash after injection
- Do not receive filgrastim within 24 hours of chemotherapy—confirm schedule with oncology team
- Store in refrigerator; let syringe warm per instructions; do not shake; rotate injection sites for home use
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- ANC >10,000/mm³ after chemotherapy-induced nadir (or WBC >100,000/mm³ during PBPC mobilization per labeling)
- Cytotoxic chemotherapy given within the past 24 hours or scheduled within the next 24 hours
- Left upper quadrant or left shoulder pain, suspected splenomegaly, or splenic rupture
- Fever with pulmonary infiltrates or respiratory distress pending ARDS evaluation; active sickle cell crisis
- Serious allergic reaction to filgrastim/pegfilgrastim, particulate/discolored product, wrong patient/product/dose, or cutaneous vasculitis until prescriber re-evaluates
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Oncology nurses bridge chemotherapy timing, lab trends, and injection safety. Filgrastim is not a routine subcutaneous dose when the 24-hour chemo window or ANC ceiling is violated.
1. Check-before-you-give protocol
- Right patient, filgrastim product (not pegfilgrastim), mcg/kg dose, route, and indication
- Last cytotoxic chemotherapy >24 hours ago; next chemo not within 24 hours
- Latest ANC below prescriber/label hold threshold; platelet count reviewed if protocol requires
- Abdominal pain assessment and allergy history reviewed; refrigerator product at room temp per labeling
2. High-alert and safety badge
Not universally high-alert — treat as high-risk biologicAlthough not on every institutional high-alert list, filgrastim carries fatal splenic rupture reports and strict chemotherapy timing rules—use independent double-checks for product, mcg/kg math, and chemo window.
3. Clinical workflow: hold and question rules
- If ANC is 11,200/mm³ on morning labs and daily filgrastim is due, hold and notify prescriber same day—document trend
- If chemotherapy finished 18 hours ago and MAR lists filgrastim now, hold until 24-hour window confirmed with pharmacy
- Left shoulder pain after yesterday’s dose → hold further G-CSF, notify prescriber, prepare urgent assessment pathway
4. Critical teach-back questions
- “What pain should you report right away?” (Patient should name left upper belly or left shoulder pain and say they will call immediately—not wait for the next dose.)
- “When should you NOT get this injection relative to chemotherapy?” (Patient should explain filgrastim must not be given within 24 hours before or after chemo and they will confirm timing with the team.)
5. Care coordination
Oncology / hematology team: Chemotherapy schedule, ANC thresholds, hold/resume after splenic symptoms, and transition between filgrastim and pegfilgrastim
Pharmacist: Biosimilar verification, mcg/kg calculation from prefilled syringes, 24-hour timing clarification, and interaction review
🧠 Quick mental checklist
- Has it been more than 24 hours since cytotoxic chemotherapy ended?
- What is today’s ANC—and is it already above 10,000/mm³?
- Any left upper quadrant or shoulder pain today?
- Correct G-CSF product (filgrastim vs pegfilgrastim) and mcg/kg dose for current weight?
- Fever, breathing change, or allergic symptoms since the last dose?
Filgrastim NCLEX practice questions
Practice NCLEX-style clinical judgment practice for filgrastim splenic and neutropenia safety using a tabbed oncology case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), ANC trend interpretation, matrix urgency sorting, clinical judgment, and chemotherapy-timing cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Filgrastim (Neupogen) 5 mcg/kg SC daily — 0900 due now
- Cycle 3 doxorubicin + cyclophosphamide completed yesterday 1400 (22 hours ago)
- Acetaminophen 650 mg PO PRN bone pain — given at 0700
- Ondansetron 8 mg PO q8h PRN nausea
- Pharmacy note: verify weight 62 kg → ordered dose 310 mcg from 480 mcg/0.8 mL syringe
- Day 0 (pre-chemo): WBC 6.2 × 10³/µL; ANC 4.1 × 10³/µL
- Day 5 (nadir): WBC 1.1 × 10³/µL; ANC 0.3 × 10³/µL
- Day 7 (filgrastim day 2): WBC 4.8 × 10³/µL; ANC 2.9 × 10³/µL
- Today day 8 AM: WBC 9.6 × 10³/µL; ANC 8.4 × 10³/µL; platelets 142 × 10³/µL
- T 37.4 °C; HR 96; RR 18; BP 118/72; SpO₂ 97% on room air
- Reports moderate bone pain in sternum and thighs (familiar from prior cycles)
- New complaint: aching at left shoulder tip started overnight
- Abdominal exam: mild tenderness left upper quadrant; no rebound documented yet
- 0700: Patient asked if filgrastim can be given “right after chemo like last month”—verify timing; prior cycle dose was delayed for 24 h window
- 0800: Night nurse documented shoulder pain; splenic rupture teaching not yet reinforced this admission
- 0845: Student prepared 480 mcg syringe; instructor paused for weight-based check
- Plan: daily filgrastim until ANC >10,000/mm³ after nadir per prescriber note
Answer key & rationale
Frequently asked questions
Why must filgrastim be given at least 24 hours after chemotherapy?
Neupogen labeling states safety and efficacy are not established when filgrastim is given simultaneously with cytotoxic chemotherapy because rapidly dividing myeloid cells are sensitive to chemotherapy. Do not use filgrastim in the 24-hour period before through 24 hours after chemotherapy administration.
When should nurses stop filgrastim for high ANC?
For chemotherapy-induced neutropenia, Neupogen labeling recommends discontinuing filgrastim if ANC increases beyond 10,000/mm³ after the chemotherapy-induced nadir. Monitor CBC at least twice weekly during therapy.
What symptoms suggest splenic rupture on filgrastim?
Labeling directs evaluation for splenomegaly or splenic rupture when patients report left upper abdominal or shoulder pain. Splenic rupture including fatal cases has occurred with filgrastim products—discontinue and escalate urgently if suspected.
Is there an antidote for filgrastim overdose?
No specific antidote is listed in Neupogen labeling. Management includes discontinuing or reducing filgrastim and monitoring CBC. Contact local poison control or medical toxicology services per facility protocol and local emergency guidance.
Can filgrastim be given during pregnancy or breastfeeding?
Human data have not established major birth defect or miscarriage risk, but animal studies show adverse effects at supratherapeutic doses. Filgrastim transfers into breast milk. Use during pregnancy or lactation only when potential benefit justifies potential risk—coordinate with prescriber.
References
-
U.S. FDA DailyMed — Neupogen (filgrastim) injection prescribing informationhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193
-
U.S. FDA DailyMed — Granix (tbo-filgrastim) injection prescribing informationhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df918ec2-0907-443f-a52a-b72866959644
-
StatPearls — Filgrastim (NCBI Bookshelf)https://www.ncbi.nlm.nih.gov/books/NBK559282/
-
National Comprehensive Cancer Network (NCCN) — clinical practice resourceshttps://www.nccn.org/
-
American Society of Hematology (ASH) — hematology education resourceshttps://www.ash.org/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.